Drug Trial Radar · NCT05653219
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
152
Actual
Start
Feb 2, 2023
Primary completion
Jun 19, 2025
Study completion Apr 8, 2028
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of two different doses of ianalumab added to eltrombopag to prolong Time to Treatment Failure (TTF) in adults with primary ITP who failed previous first-line treatment with steroids.
Conditions
- Primary Immune Thrombocytopenia
Interventions
IanalumabBiological
Concentrate for solution for infusion for intravenous use
EltrombopagDrug
Film-coated tablet for oral use
PlaceboDrug
Concentrate for solution for infusion for intravenous use.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time from randomization until treatment failureTime frame: Randomization to until end of study (up to 39 months after randomization of last participant)
Locations
74 sites in 24 countries. Site status is shown where the registry gives one.
Yuma Regional Medical Center
Yuma, Arizona
University of Colorado Anschutz
Aurora, Colorado
Endeavor Health
Evanston, Illinois
Boston Medical Center
Boston, Massachusetts
UMASS Memorial Medical Center
Worcester, Massachusetts
Michigan Center of Medical Research
Farmington Hills, Michigan
St Vincent Frontier Cancer Center
Billings, Montana
Hematology Oncology Association of Rockland
Nyack, New York
Montefiore Medical Center
The Bronx, New York
Novartis Investigative Site
CABA, Argentina
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Yvoir, Namur, Belgium
Novartis Investigative Site
Roeselare, West Vlaanderen, Belgium
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Jinan, China
Novartis Investigative Site
Tianjin, China
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Wuhan, Hubei, China
Novartis Investigative Site
Binzhou, Shandong, China
Novartis Investigative Site
Hangzhou, Zhejiang, China
Novartis Investigative Site
Brno, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Blois, France
Novartis Investigative Site
Le Mans, France
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site
Dresden, Saxony, Germany
Novartis Investigative Site
Jena, Thuringia, Germany
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Debrecen, Hajdu Bihar Megye, Hungary
Novartis Investigative Site
Rishikesh, Uttarakhand, India
Novartis Investigative Site
Kolkata, West Bengal, India
Novartis Investigative Site
Bologna, BO, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Trieste, TS, Italy
Novartis Investigative Site
Kumamoto, Japan
Novartis Investigative Site
Nagoya, Aichi-ken, Japan
Novartis Investigative Site
Osaka, Osaka, Japan
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.